Abstract
Thyroid cancer therapy using I-131 has already used widely to help ablate thyroid remnants, but many patients still not convinced whether this therapy really ablate thyroid or not and their distribution in the body, also about the effect of metabolic process on decreasing the exposure rate of the body so that patient can go home early. By exposure rate of the body and urine of the patient, will be determined the uptake percentage, absorbed dose, absorption rate, and washing out percentage that helped to determine the probability of radioiodine absorption in thyroid compared to other organs and effect of metabolic process on decreasing the body exposure rate of the patient. This research will be focused to prove that this therapy indeed being absorbed more in thyroid rather in other organs and by increasing the metabolic activity, the exposure rate of the patient will decrease faster which means that the treatment going faster and reduce the queue of this therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have